Our proprietary technology builds on the same principles that made Doxil®, the first FDA-approved Nanomedicine using liposomal drug delivery, a success. We apply these principles to treat infectious diseases and cancer by encapsulating potent therapeutics in novel lipid-based particles. By encapsulating potent therapeutics within novel lipid-based particles, we achieve controlled drug release, targeted delivery, and extended circulation time, ultimately leading to greater efficacy and fewer systemic side effects.

Liposomes are one of the best drug delivery systems, offering protection from degradation, enhanced bioavailability, and reduced toxicity. ReviumRx harnesses these advantages and the enhanced permeability and retention (EPR) effect to ensure targeted drug accumulation in tumors and infected tissues, maximizing potency while minimizing harm to healthy cells.

Our intellectual property is developed by renowned scientist Prof. Barenholz, a pioneer in liposomal drug delivery. His team played a pivotal role in establishing liposomal technology as a cornerstone of one of the leading anticancer therapies. Our technology represents the culmination of decades of groundbreaking research in nanomedicine, and ReviumRx is now expanding these innovations to address critical unmet needs in infectious diseases and advanced cancer treatments.